Abstract
Affective disorders in patients with Parkinson's disease (PD) are significantly more common than in the general population in people of the same age. It is known that the ef ficacy of antidepressants in PD patients is lower than in patients with a depressive disorder not associated with PD. Therefore, such patients may take high doses of antidepressants, which is accompanied by side effects manifestations and a decrease in quality of life. Transcranial magnetic stimulation (TMS) is a safe treatment for depressive disorder that has been successfully used in PD patients. The article presents a comparison of the effectiveness of complex therapy with TMS and SSRIs with SSRI monotherapy for the treatment of depressive disorder in PD patient.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
